Consolidative32P after second-look laparotomy for ovarian carcinoma

Abstract

We report our experience with consolidative 32P after second‐look laparotomy. Forty‐three patients received consolidative 32P after platinum‐based chemotherapy and a negative (39 patients, 91%) or positive (4 patients) second‐look laparotomy. Thirty‐one patients (72%) initially had stage III (30 patients) or stage IV (1 patient) disease; 28 patients (65%) had grade 3 tumors. Patients had follow‐up from 3.5 to 14.9 years (median, 7.7 years); no patient was lost to follow‐up. The 5‐year rates of control of disease within the abdomen (local control) for the overall group and the subset of patients with stage II‐IV disease and a negative second‐look laparotomy were 65% and 69%, respectively. The corresponding 5‐year survival rates were 78 and 81%, respectively. Multivariate analyses revealed that tumor found at second‐look laparotomy significantly influenced the likelihood of local control and cause‐specific survival. Acute side effects included cellulitis (1 patient) and ileus (3 patients). Two patients (5%) experienced severe late complications; both experienced small bowel obstruction that necessitated surgical intervention. Consolidative 32P appears to reduce the risk of recurrence and improve survival after negative second‐look laparotomy. The risk of significant complications is low. Radiat. Oncol. Invest. 6:97–102, 1998. © 1998 Wiley‐Liss, Inc.